What's in Etablissement Français du Sang's pipeline?

Etablissement Français du Sang has 6 drugs in our index: 3 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 3 in Phase 1.

Which companies overlap with Etablissement Français du Sang's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/etablissement-fran-ais-du-sang.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Etablissement Français du Sang — Portfolio Competitive Intelligence Brief

Etablissement Français du Sang pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Area
Autologous plasma	Autologous plasma	marketed
Additive solution	Additive solution	marketed
Pathogen reduction process	Pathogen reduction process	marketed	Blood product safety technology	Hematology / Transfusion Medicine

Therapeutic area mix

Hematology / Transfusion Medicine · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Etablissement Français du Sang:

Cite this brief

Drug Landscape (2026). Etablissement Français du Sang — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/etablissement-fran-ais-du-sang. Accessed 2026-05-16.